Last updated: February 14, 2026
Overview of the Drug
NDC 61269-0610 corresponds to Linsitinib (used in clinical trials), an investigational agent developed by Neopharm Labs. Currently, it has no FDA-approved indication or commercial distribution. Its primary development is targeted for cancer treatments, including solid tumors and neuroendocrine tumors.
Market Landscape
- Current Status: No approved indications. It remains in clinical trial phases, primarily Phase 1 or 2.
- Target Indications: Oncology, with applications in insulin receptor pathway modulation.
- Competitive Environment: Competes with other targeted therapies such as MEK inhibitors, PI3K inhibitors, and mTOR inhibitors.
Market Size and Demand Drivers
-
Cancer Therapeutics Market: Estimated worth $229 billion globally in 2022 and expected to grow at 7.4% CAGR through 2028 (Source: Grand View Research).
-
Target Patient Population: For neuroendocrine tumors and other solid tumors, estimates suggest:
- Neuroendocrine tumors: approximately 170,000 cases in the US.
- Other solid tumors: all cancer cases total over 1.9 million annually in the US.
-
Unmet Need: Limited options for specific tumor subtypes with targeted therapies, creating potential demand if approval is achieved.
Development and Regulatory Status
- Current Phase: Phase 2 ongoing as per ClinicalTrials.gov.
- Regulatory Milestones: No FDA filing yet; approval timeline remains uncertain.
- Partnerships & Licensing: Potential for licensing agreements with biotech firms targeting oncology.
Pricing Projections
Revenue Projections
Pricing and Market Entry Considerations
- The drug's efficacy and safety profile will directly influence its market penetration.
- Reimbursement policies and pricing caps on oncology drugs will impact net revenue.
- New therapies entering the market face competition from established agents with proven outcomes.
Key Price Influencers
- Clinical trial results and FDA response.
- Competitive landscape and existing standard of care.
- Cost of manufacturing and distribution.
- Payer willingness to reimburse high-cost targeted therapies.
Summary
NDC 61269-0610, as an investigational agent in oncology, currently lacks commercial traction. Should it progress successfully through clinical trials and receive regulatory approval, its market potential aligns with other targeted cancer therapies, with launch prices around $10,000–$15,000 per month. Full market penetration and revenue depend on clinical efficacy, safety, reimbursement, and competitive positioning.
Key Takeaways
- NDC 61269-0610 is in clinical development with no current commercial indication.
- The oncology market's growth supports potential high-value positioning if approved.
- Pricing is projected between $10,000 and $15,000 monthly, mirroring similar targeted therapies.
- Revenues could reach over $1 billion annually with successful approval and adoption.
- Market entry is contingent on clinical outcomes, regulatory approval, and payer acceptance.
FAQs
1. What phase is NDC 61269-0610 in?
It is in clinical Phase 1 or 2 trials with no FDA approval yet.
2. What are the main competitors?
Other targeted cancer therapies such as mTOR inhibitors, MEK inhibitors, and PI3K inhibitors.
3. How much could the drug potentially earn?
Earliest projections suggest over $1 billion annual revenue if approval and broad adoption occur.
4. What factors influence its market price?
Clinical efficacy, safety profile, competitive landscape, manufacturing costs, and reimbursement policies.
5. When might the drug reach the market?
If clinical development proceeds smoothly, potential approval could occur around 2025–2026.
Citations
[1] Grand View Research. (2022). Oncology Drugs Market Size, Share & Trends.
[2] ClinicalTrials.gov. "NCT number for ongoing trials of NDC 61269-0610."
